Risk factor
Very poor trading liquidity
Profitability factor
Undervalued vs peers
About
Laboratorios Richmond S.A.C.I.F. is a pharmaceutical firm focused on the development and production of a diverse range of medicinal products. Their extensive portfolio includes antiretroviral treatments for human immunodeficiency virus (HIV), as well as therapies for oncology and oncohematology conditions. The company also supplies various cardiometabolic medications, such as those for blood pressure reduction, cholesterol management, platelet aggregation inhibition, and blood sugar control. Additionally, they produce neurological and psychiatric drugs, covering analgesics, antipsychotics, antidepressants, anti-dementia agents, antiepileptics, hypnotics, and treatments for multiple sclerosis. These pharmaceutical offerings are distributed across Latin America, Africa, Asia, and the Middle East. Founded in 1935, Laboratorios Richmond S.A.C.I.F. is headquartered in Buenos Aires, Argentina.
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITD.